Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events

Area of Science:

• Cardiology
• Preventive Medicine
• Public Health

Background:

• The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines introduced new criteria for statin therapy eligibility.
• The effectiveness of these new guidelines in identifying high-risk individuals for cardiovascular events (CVD) compared to previous guidelines remains unclear.

Purpose of the Study:

• To compare the ability of the 2013 ACC/AHA guidelines versus the 2004 National Cholesterol Education Program's Adult Treatment Panel III (ATP III) guidelines in identifying individuals who develop incident CVD or have coronary artery calcification (CAC).

Main Methods:

• A longitudinal community-based cohort study using data from the Framingham Heart Study (offspring and third-generation cohorts).
• Participants underwent computed tomography for CAC assessment and were followed for incident CVD over a median of 9.4 years.
• Statin eligibility was determined using the ACC/AHA pooled cohort calculator and ATP III criteria.

Main Results:

• The ACC/AHA guidelines identified 39% of participants as statin-eligible compared to 14% under ATP III (P < .001).
• ACC/AHA-eligible individuals had higher hazard ratios for incident CVD (6.8 vs. 3.1, P < .001) and CHD compared to ATP III-eligible individuals.
• The ACC/AHA guidelines demonstrated improved identification of CVD risk, particularly in intermediate-risk participants and those with detectable CAC.

Conclusions:

• The 2013 ACC/AHA cholesterol guidelines are more accurate and efficient than ATP III in identifying individuals at increased risk for incident CVD and subclinical coronary artery disease.
• These findings support the utility of the ACC/AHA guidelines in primary prevention strategies for cardiovascular disease.